Login / Signup

A Phase 1, open-label, crossover study evaluating the effect of a single dose of sodium zirconium cyclosilicate on the pharmacokinetics of tacrolimus and cyclosporin.

Mats NågårdNurul ChoudhuryAyman Al-ShurbajiVera LisovskajaNeil Mackillop
Published in: Clinical kidney journal (2022)
Tacrolimus exposure was lower when co-administered with SZC 15 g and should be administered ≥2 h before or after SZC. The PK profile of cyclosporin was not affected by SZC co-administration.
Keyphrases
  • open label
  • clinical trial
  • phase ii
  • study protocol
  • phase ii study
  • phase iii
  • randomized controlled trial
  • rectal cancer